BioSpace News Archive

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that it will present new results and a clinical study overview at the Phase I and First-in-Human Clinical Trials in Progress Session at the 2023 American Association of Cancer Research (AACR) Annual Meeting to be held April 14-19.

Evopoint Biosciences Co., Ltd.(“Evopoint”) announced today a collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA) to evaluate Evopoint’s XNW5004, a selective EZH2 inhibitor, in combination with KEYTRUDA®(pembrolizumab), MSD’s anti-PD-1 therapy, in a Phase Ib/II study in Chinese patients with advanced solid tumors.

QurAlis Corporation today announced that the first patient has been dosed in its Phase 1 clinical trial of QRL-201 for the treatment of ALS (ANQUR).

electroCore, Inc., a commercial-stage bioelectronic medicine and wellness company, announced the receipt of a license to import, distribute and market gammaCore Sapphire™, non-invasive vagus nerve stimulator in Indonesia.

Spectral Medical Inc., a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, announced details for the Company’s 2023 Investor Update conference call.

Recce Pharmaceuticals Ltd, the Company developing a new class of synthetic anti-infectives, is pleased to announce it received additional non-dilutive funds from Radium Capital for A$973,144 for Recce’s future research and development tax incentive.

Extendicare Inc. announced that it plans to release its financial results for the first quarter of 2023 after market close on Thursday, May 4, 2023.

Immuron Limited is pleased to announce the Q3 FY23 sales* results of its over-the-counter gastrointestinal and digestive health immune supplement Travelan® and Protectyn®.

ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced it has entered into a term loan financing facility for up to $175 million with entities managed by Pharmakon Advisors, LP.

Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that Devyn Smith, Ph.D., Arbor’s Chief Executive Officer and the Chairman of Alliance for Regenerative Medicine, will give welcoming remarks and present at the annual Cell & Gene Meeting on the Med.